Edwards pushes CMS to expand Medicare TAVR coverage as agency opens public comment period through January 2026 for decision.

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

Atrioventricular blocks occurring during transcatheter aortic valve replacement differ from those occurring after the ...

Medicare reimbursement for aortic stenosis patients without symptoms could accelerate procedure growth for Edwards ...

Of the two heart valve surgeries Janice Smith has had at OhioHealth Mansfield Hospital, the second was much easier for her. "I had a good experience both times," the 86-year-old said. "It's just that ...

The global, multibillion-dollar transcatheter heart valves market will grow at an 8.4% CAGR over the rest of the 2020s, ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...

Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...

Upgraded Medtronic to a ‘Buy’ rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2 ...